Frequently Asked Questions

Below are answers to the questions our research team receives most often.

🛡 Is every batch independently tested?

Yes. Every batch we supply is independently analysed using HPLC by Janoshik Analytical, an independent peptide testing laboratory based in the Czech Republic.

Our products consistently achieve greater than 99% purity.

When a Certificate of Analysis (COA) is available for the current production batch, a printed copy is included with your order. If the latest report is still pending, batch verification can be accessed through our Purity page.

Each COA contains a unique verification code that can be validated directly through Janoshik’s online verification system, allowing researchers to independently confirm the authenticity of the report.

We also provide a detailed guide explaining how to interpret Janoshik HPLC reports.

---

💧 Reconstituting the Lyophilised Peptide

Follow these four simple steps:

1. Clean the vial stopper with an alcohol wipe and allow it to air dry.
2. Withdraw 2 mL of bacteriostatic water using an insulin syringe.
3. Slowly inject the solution down the inside wall of the peptide vial rather than directly onto the powder.
4. Gently swirl the vial until the powder has completely dissolved. Avoid shaking, then refrigerate.

A reconstitution reference guide is included inside the product packaging for future use.

---

💉 Using the Research Dose Pen

1. Attach a new sterile needle after wiping the pen tip with an alcohol swab.
2. Prime the pen by selecting one click, pointing the needle upward, and pressing the dose button until a small droplet appears.
3. Dial the desired research dose. Each click delivers a predetermined increment based on the pen calibration.
4. Follow the administration route described in the published research protocol. Hold the pen in position for approximately six seconds before withdrawing.
5. Dispose of the used needle in an approved sharps container, replace the cap, and refrigerate the pen.

Each pen provides the number of doses shown in the protocol guide for your selected cartridge size. Once empty, simply replace the cartridge while continuing to use the same pen body.

Research use only. The information above reflects published research procedures and is not intended as medical or clinical guidance.

---

❄ Storage Recommendations

Lyophilised Powder

• Store between 2–8°C
• Protect from light
• Stable for at least 24 months
• Do not freeze

After Reconstitution

• Refrigerate at 2–8°C
• Keep in the original glass vial
• Do not shake
• Recommended use within approximately 30 days
• Discard if the solution becomes cloudy or changes colour

Bacteriostatic Water

• Refrigerate after opening
• Use within 30 days

---

📍 Administration Route Reported in Published Research

Published pharmacokinetic and Phase II/III studies involving ARA290 (Cibinetide) have generally utilised subcutaneous administration, commonly in the abdomen, thigh, or upper arm. Research protocols typically recommend rotating administration sites to minimise local tissue irritation.

This information is provided as a summary of published scientific literature only.

Research use only. We do not provide dosing advice, administration recommendations, or human-use guidance.

Reference: Brines et al. (2008).

---

🎯 What Research Dose Should Be Used?

The recommended approach is to follow the protocol schedule provided above.

Published studies involving ARA290 typically use a gradual dose-escalation (titration) strategy, beginning with the lowest phase before progressing at scheduled intervals. Most ongoing research protocols stabilise at the maintenance phase highlighted in the protocol.

Researchers beginning work with this compound should complete the initial phase before advancing to the next stage, as gradual titration was incorporated into published studies.

Researchers already familiar with ARA290 can select the protocol phase appropriate for their study and use the calculator above to estimate vial longevity and overall cost.

If your research follows a customised protocol, contact our team before placing your order. We can help determine the most suitable presentation for your study design.

Research use only. The information above summarises published scientific literature and is provided solely for research reference. It should not be interpreted as medical advice or guidance for human use.

Reference: Brines et al. (2008).

---

Key Information

Specification	Details
Compound	ARA290 (Cibinetide)
Research Category	Regenerative Research
Available Sizes	10 mg, 16 mg
Price	From £55
Presentation	Lyophilised powder in a sealed vial
Purity	>99% (HPLC verified by Janoshik Analytical)
Intended Use	In vitro laboratory research only. Not for human consumption.

---

Chemical & Reference Information

The following data is compiled from publicly available scientific databases and peer-reviewed publications.

Property	Description
Compound Class	Synthetic 11-amino-acid peptide derived from erythropoietin helix B
Molecular Formula	C₅₁H₈₂N₁₆O₂₀
Molecular Weight	1257.4 g/mol
CAS Number	1239358-86-1
Amino Acid Residues	11
Sequence	QEQLERALNSS
Biological Target	Innate Repair Receptor (EPOR/βcR heteromer) agonist
Haematopoietic Activity	Non-erythropoietic
Reported Half-Life	Approximately 2 minutes in human serum
Solubility	Readily reconstituted with bacteriostatic water for laboratory use
Lyophilised Storage	Stable at 2–8°C for 24+ months
Reconstituted Storage	Store at 2–8°C and typically use within 14 days
Clinical Status	Investigated in Phase II clinical research

---

Research Profile

• Synthetic 11-amino-acid peptide
• Derived from erythropoietin helix B
• Selective non-haematopoietic EPO analogue
• Investigated in tissue repair research models
• Independently HPLC batch tested
• Intended exclusively for laboratory research

ARA290 (Cibinetide) is a synthetic peptide derived from the B-helix region of erythropoietin. Published research characterises the compound as a selective agonist of the Innate Repair Receptor (EPOR/βcR complex) while lacking the erythropoietic activity associated with native erythropoietin.

It is supplied as a lyophilised powder for in vitro laboratory research only.

The description above summarises findings reported in peer-reviewed scientific literature and should not be interpreted as evidence of clinical efficacy or therapeutic benefit.

---

Laboratory Handling

ARA290 is supplied as a freeze-dried powder in a sealed glass vial.

For laboratory preparation, slowly introduce the chosen volume of bacteriostatic water down the inner wall of the vial. Gently swirl until fully dissolved, avoiding vigorous agitation or vortex mixing.

Following reconstitution, store the solution at 2–8°C. Under typical laboratory conditions, prepared solutions are commonly used within 4–6 weeks.

Our Reconstitution Volume Calculator can be used to determine the final concentration (mg/mL).

Preparation State	Storage Temperature	Typical Stability
Lyophilised	2–8°C or -20°C	Up to 24 months
Reconstituted	2–8°C	Approximately 4–6 weeks

---

Purity & Batch Verification

Every production batch undergoes independent HPLC analysis by Janoshik Analytical.

Where available, a batch-specific Certificate of Analysis accompanies each order. Every certificate includes a unique verification code that can be confirmed directly through Janoshik’s verification portal, providing independent confirmation of the reported analytical results.

Reported purity consistently exceeds 99%.

---

Related Research Compounds

Researchers investigating ARA290 frequently reference the following compounds in the scientific literature:

• BPC-157 — Regenerative Research
• TB-500 — Regenerative Research